<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05696080</url>
  </required_header>
  <id_info>
    <org_study_id>V116-008</org_study_id>
    <secondary_id>V116-008</secondary_id>
    <secondary_id>jRCT2061220106</secondary_id>
    <nct_id>NCT05696080</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)</brief_title>
  <acronym>STRIDE-8</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and tolerability of the&#xD;
      pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific&#xD;
      opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal&#xD;
      conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from&#xD;
      23 of the serotypes causing disease in adults) post-vaccination. within each vaccination&#xD;
      group separately.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2023</start_date>
  <completion_date type="Anticipated">February 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with solicited injection-site adverse events (AEs) from Day 1 through Day 5 post-vaccination</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>Percentage of participants with solicited injection-site AEs from Day 1 through Day 5 post-vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with solicited systemic AEs from Day 1 through Day 5 post-vaccination</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>Percentage of participants with solicited systemic AEs from Day 1 through Day 5 post-vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with vaccine-related serious adverse events (SAEs) from Day 1 through the duration of participation in the study</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Percentage of participants with vaccine-related SAEs from Day 1 through the duration of participation in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) post-vaccination</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Serotype-specific OPA GMTs post-vaccination with V116 (30 days post-vaccination [Day 30]) or PCV15 + PPSV23 (30 days post-vaccination with the final dose in the regimen [Week 12])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) post-vaccination</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Serotype-specific IgG GMCs post-vaccination with V116 (Day 30) and PCV15 + PPSV23 (Week 12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific geometric mean fold rises (GMFRs) from baseline to post-vaccination with V116 and PCV15 + PPSV2 for OPA responses</measure>
    <time_frame>Baseline and up to Week 12</time_frame>
    <description>Serotype-specific GMFRs from baseline (Day 1) to post-vaccination with V116 (Day 30) and from baseline (Day 1) to post=vaccination with PCV15 + PPSV2 (Week 12) for OPA responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific GMFRs from baseline to post-vaccination with V116 and PCV15 + PPSV2 for Immunoglobulin G (IgG) responses</measure>
    <time_frame>Baseline and up to Week 12</time_frame>
    <description>Serotype-specific GMFRs from baseline (Day 1) to post-vaccination with V116 (Day 30) and from baseline (Day 1) to post-vaccination with PCV15 + PPSV23 (Week 12) for IgG responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific percentage of participants with a ≥4-fold rise from baseline to post-vaccination with V116 and PCV15 + PPSV2 for OPA responses</measure>
    <time_frame>Baseline and up to Week 12</time_frame>
    <description>Serotype-specific percentage of participants with a ≥4-fold rise from baseline (Day 1) to post-vaccination with V116 (Day 30) and from baseline (Day 1) to post-vaccination with PCV15 + PPSV2 (Week 12) for OPA responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific percentage of participants with a ≥4-fold rise from baseline to post-vaccination with V116 and PCV15 + PPS for IgG responsesV2</measure>
    <time_frame>Baseline and up to Week 12</time_frame>
    <description>Serotype-specific proportion of participants with a ≥4-fold rise from baseline (Day 1) to post-vaccination with V116 (Day 30) and from baseline (Day 1) to post-vaccination with PCV15 + PPSV2 (Week 12) for IgG responses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>V116</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo for PCV15 + PPSV23 on Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV15 + PPSV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V116</intervention_name>
    <description>Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution</description>
    <arm_group_label>V116</arm_group_label>
    <other_name>Pneumococcal 21-valent Conjugate Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for PCV15 + PPSV23</intervention_name>
    <description>Saline in each 0.5 mL sterile solution</description>
    <arm_group_label>V116</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV15</intervention_name>
    <description>Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension</description>
    <arm_group_label>PCV15 + PPSV23</arm_group_label>
    <other_name>VAXNEUVANCE™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPSV23</intervention_name>
    <description>Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution</description>
    <arm_group_label>PCV15 + PPSV23</arm_group_label>
    <other_name>PNEUMOVAX™23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has documented result(s) of ≥1 of the following risk conditions for pneumococcal&#xD;
             disease: diabetes mellitus, receiving treatment with ≥1 approved antidiabetic&#xD;
             medication, with all Hemoglobin A1c (HbA1c) measurements ≤9% within 6 months before&#xD;
             first study vaccination; compensated chronic liver disease; diagnosis of chronic&#xD;
             obstructive pulmonary disease (COPD) managed per local guidelines; diagnosis of mild&#xD;
             or moderate persistent asthma managed per local guidelines; confirmed diagnosis of&#xD;
             chronic heart disease managed per local guidelines; confirmed diagnosis of chronic&#xD;
             kidney disease (&gt;3 months duration).&#xD;
&#xD;
          -  Is receiving stable medical management for the listed risk conditions for ≥3 months&#xD;
             with no anticipated major change in treatment expected for the duration of the study&#xD;
             and with ≤1 hospitalization directly related to the risk condition.&#xD;
&#xD;
          -  Female Is not a participant of childbearing potential (POCBP); or if a POCBP Uses an&#xD;
             acceptable contraceptive method or is abstinent from penile-vaginal intercourse as&#xD;
             their preferred and usual lifestyle (abstinent on a long-term and persistent basis);&#xD;
             their medical history, menstrual history, and recent sexual activity has been reviewed&#xD;
             by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of active hepatitis.&#xD;
&#xD;
          -  Has a history of diabetic ketoacidosis or 2 or more episodes of severe, symptomatic&#xD;
             hypoglycemia within 3 months before first study vaccination (Day 1).&#xD;
&#xD;
          -  Has a history of myocardial infarction, acute coronary syndrome, transient ischemic&#xD;
             attack, or ischemic or hemorrhagic stroke within 3 months before first study&#xD;
             vaccination (Day 1).&#xD;
&#xD;
          -  Has a history of severe pulmonary hypertension with World Health Organization (WHO)&#xD;
             functional class ≥3 or history of Eisenmenger syndrome&#xD;
&#xD;
          -  Has a history of autoimmune related chronic kidney disease, chronic kidney failure, a&#xD;
             reversible cause of kidney disease, nephrotic syndrome, or any ineligible Kidney&#xD;
             Disease: Improving Global Outcomes (KDIGO)-recommended stage of glomerular filtration&#xD;
             rate (GFR) and Albuminuria&#xD;
&#xD;
          -  Has a history of invasive pneumococcal disease (IPD) (positive blood culture, positive&#xD;
             cerebrospinal fluid culture, or positive culture at another sterile site) or known&#xD;
             history of other culture-positive pneumococcal disease within 3 years before first&#xD;
             study vaccination (Day 1).&#xD;
&#xD;
          -  Has a known hypersensitivity to any component of V116, PCV15, or PPSV23, including&#xD;
             diphtheria toxoid.&#xD;
&#xD;
          -  Has a known or suspected impairment of immunological function including, but not&#xD;
             limited to, congenital or acquired immunodeficiency, documented human immunodeficiency&#xD;
             virus (HIV) infection, functional or anatomic asplenia, or autoimmune disease.&#xD;
&#xD;
          -  Has a coagulation disorder contraindicating intramuscular (IM) vaccination.&#xD;
&#xD;
          -  Had a recent febrile illness or received antibiotic therapy for any acute illness&#xD;
             occurring within 72 hours before receipt of any study vaccine.&#xD;
&#xD;
          -  Has a known malignancy that is progressing or has required active treatment &lt;3 years&#xD;
             before randomization.&#xD;
&#xD;
          -  Has planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other&#xD;
             planned major surgical procedure during the duration of this study.&#xD;
&#xD;
          -  Has expected survival for &lt;1 year.&#xD;
&#xD;
          -  Has received any prior pneumococcal vaccine or is expected to receive any pneumococcal&#xD;
             vaccine during the study outside the protocol.&#xD;
&#xD;
          -  Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14&#xD;
             consecutive days and has not completed intervention ≥14 days before receipt of study&#xD;
             vaccine at Visit 2 (Day 1).&#xD;
&#xD;
          -  Is currently receiving systemic immunosuppressive therapy, including chemotherapeutic&#xD;
             agents or other immunotherapies/immunomodulators used to treat cancer or other&#xD;
             conditions, and interventions associated with organ or bone marrow transplantation, or&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Has received any non-live vaccine ≤14 days before receipt of any study vaccine or is&#xD;
             scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine.&#xD;
&#xD;
          -  Has received any live virus vaccine (including severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) live virus vaccines) ≤30 days before receipt of any study&#xD;
             vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of&#xD;
             any study vaccine&#xD;
&#xD;
          -  Has received a blood transfusion or blood products, including immunoglobulin ≤6 months&#xD;
             before receipt of any study vaccine or is scheduled to receive a blood transfusion or&#xD;
             blood product ≤30 days after receipt of any study vaccine.&#xD;
&#xD;
          -  Is receiving chronic home oxygen therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aventiv Research ( Site 0022)</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-229-2829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc ( Site 0002)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-825-6588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A ( Site 0011)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SKY Integrative Medical Center/SKYCRNG ( Site 0012)</name>
      <address>
        <city>Ridgeland</city>
        <state>Mississippi</state>
        <zip>39157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-659-4363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research ( Site 0008)</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>845-674-9398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>EmVenio Research ( Site 0018)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>949-246-8280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group ( Site 0010)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>423-857-2789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital ( Site 0019)</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-436-4050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 0402)</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61280381044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital ( Site 0400)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 499 947 531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>G A Research Associates ( Site 0100)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068529865</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group ( Site 0107)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055451376212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milestone Research Inc. ( Site 0106)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5196594040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research Mirabel ( Site 0105)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>450-420-0270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Victoriavile Inc. ( Site 0102)</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819-820-5488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernán Henríquez Aravena ( Site 1001)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>(5699) 885-8673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010)</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56712412716</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidad San Sebastian - Providencia ( Site 1003)</name>
      <address>
        <city>Providencia</city>
        <state>Region M. De Santiago</state>
        <zip>7500000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>569 98211521</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Respiratorias (CIMER) ( Site 1008)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56997739802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinicadela Universidad Catolica ( Site 1004)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8330034</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56981989928</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CESFAM Esmeralda ( Site 1009)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>9340000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56982488403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic ( Site 0200)</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0942-35-3705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shimonoseki Medical Center ( Site 0201)</name>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81832315811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital ( Site 0303)</name>
      <address>
        <city>Anyang-si</city>
        <state>Kyonggi-do</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82-31-380-3757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 0305)</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>082-10-4756-2931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0300)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82-2-2072-2195</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center ( Site 0302)</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82220307522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital ( Site 0301)</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02-2224-2754</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research - Tauranga ( Site 0507)</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>006475790453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CGM Research Trust ( Site 0505)</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6421554118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research - Lower Hutt ( Site 0508)</name>
      <address>
        <city>Lower Hutt</city>
        <state>Wellington</state>
        <zip>5010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6421335693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research - Wellington ( Site 0503)</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+64-4-801 0002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IN VIVO ( Site 0601)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-048</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>501109918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 0607)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48734120500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MICS Centrum Medyczne Torun ( Site 0606)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48603198347</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinmedica Research Sp. z. o. o. ( Site 0603)</name>
      <address>
        <city>Skierniewice</city>
        <state>Lodzkie</state>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48660734939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk ( Site 0602)</name>
      <address>
        <city>Rzeszow</city>
        <state>Podkarpackie</state>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048 603374080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice ( Site 0604)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48607931761</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research ( Site 0605)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-156</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>693455565</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>June 8, 2023</last_update_submitted>
  <last_update_submitted_qc>June 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

